Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne...
Transcript of Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne...
![Page 1: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/1.jpg)
![Page 2: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/2.jpg)
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow
Chemo + RT
David H. Ilson, MD, PhD
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
![Page 3: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/3.jpg)
Disclosure
Consulting
– AMGEN
– Bayer
– Lilly/Imclone
– Pieris
– Roche/Genentech
– Astra Zeneca
– Bristol Myers Squibb
– Merck
– Pfizer
– Astellas
![Page 4: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/4.jpg)
Esophageal Squamous Cancer: Neoadjuvant Therapy
Survival with surgery alone: < 20-40%
Preop Chemo or
Chemo + RT + / - Surgery
– Common Western practice
Survival improvements over surgery alone
– Older trials: 6%-12%
– CROSS for Squamous Cancer: OS 81.6 mos CRT + S vs 21.1 mos S
Why Operate after Chemo + RT?
– Improve OS
– High rate of local persistence/recurrence with Chemo RT alone
– Reduce catastrophic local failure
![Page 5: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/5.jpg)
Esophageal Squamous Cancer: Failure of Preop Chemo in the West
Preop CF failed
U.S. INT 113: 450 pts: No impact on OS, R0 59-62%
– No benefit for Squamous Cancer
MRC 0E0-2: 800 pts: 5 year 6% OS increase
– Only due to increase in R0 54% 60%
– Squamous 9% OS increase
Kelsen NEJM 1998, Alllum J Clin Oncol 2009
![Page 6: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/6.jpg)
Esophageal Squamous Cancer: Preop Chemo
Japanese Trials CF + Surgery Problematic
JCOG9210: Post op Chemo
– DFS, but no OS benefit, only in N+
JCOG9907: Preop Chemo > Post op Chemo
– In contrast to JCOG9210, No DFS benefit, no benefit for N1 disease
– OS benefit only in N0
All pts 12% 5 yr OS benefit
– Only 65% of post op pts received chemo compared to 100% preop arm
Ando JCO 2003, Ando Ann Surg Onc 2012
![Page 7: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/7.jpg)
Nonoperative Chemoradiotherapy
U.S. RTOG Trial 85-01
mskcc dhi 1999
Esophageal Ca
Locally Advanced,
Squamous Adeno
6400 cGy
Alone
5000 cGy + 5FU /
Cis x 2
+ 5-FU / Cis x 2
Herskovic NEJM 1992
![Page 8: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/8.jpg)
Local Recurrence
with ChemoRT: 45%
![Page 9: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/9.jpg)
Chemoradiotherapy + / - Surgery: Phase III, Squamous
Author Pt No.
Histol. Therapy Med. Surv.
O.S. Local Control
Stahl 86 Squam Chemo RT + S
16.4 mos
31%
3 yr (NS)
64%
86 Squam Chemo RT
14.9 mos
24%
3 yr
41%
5-FU, Cisplatin, VP16 Cis/VP16 + RT Surgery or
additional CRT
Stahl JCO 23: 2310; 2005
Treatment Mortality 12.8% CRT + S, 3.5% S
![Page 10: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/10.jpg)
Chemo RT + / - Surgery: Squamous Cancer
Overall Survival Freedom From Local Recurrence
Stahl JCO 23: 2310; 2005
![Page 11: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/11.jpg)
Chemo RT or Chemo RT Surgery only in Responding Patients: FFCD 9102
Author Pt No.
Histol. Therapy Med. Surv.
O.S. Local Control
Bedenne 259 Squam Chemo RT + S
17.7 mos
34%
2 yr
66%
Squam Chemo RT 19.3 mos
40%
2 yr
57%
455 pts, 259 responders randomized: Non responders excluded.
Bedenne et al JCO 25: 1160; 2007
Treatment Mortality S 9.3% CRT 0.8%
![Page 12: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/12.jpg)
OS in Responding Patients: CRT + / Surgery
![Page 13: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/13.jpg)
Outcome of non randomized, non responder patients: Bedenne Trial
112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71% (40% all pts)
Median OS 17.3 mo in resected pts
18 “non responder” patients had TRG 1-2 (23% resected, 16% all pts)
– Median OS not reached vs 12.7 mos partial/progression path response
Median OS of 17.3 mo non randomized pts = 18.9 mo OS randomized pts undergoing surgery patients
Surgery plays a role in non responder pts
Bedenne EJC 2015
![Page 14: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/14.jpg)
Esophageal Cancer: Predictive Accuracy of post ChemoRT Endoscopy
137 pts: Chemo RT surgery
EGD and biopsy Surgery
104 pts (76%) negative biopsy post therapy
– Poor Predictor: Only 35% had pathologic CR at surgery
A negative biopsy better predictor for squamous cell carcinoma (p <0.001)
Sarkaria JCO 24: Abs 4024, 182, 2006
![Page 15: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/15.jpg)
PET Scan and Path CR: Esophageal Cancer
493 pts, AC and Squamous, treated with preop chemo RT
PET scan prior to therapy, after chemort
PET response not associated with pCR or nodal disease
Squamous cancer patients: SUV response correlated with pCR
– SUV reduction < 50% pCR 29%, 50-75% pCR 44%
– SUV reduction > 75%: pCR 85%
Rizk J Clin Oncol 27: Abstr 4552; 2009
![Page 16: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/16.jpg)
Van Hagen et al NEJM 366: 2074; 2012
Paclitaxel 50mg/m2 + Carboplatin AUC=2 on days 1, 8, 15, 22 and 29
Concurrent radiotherapy of 41.4 Gy in 23 fractions of 1.8 Gy
Surgery within 6 weeks after completion of chemoradiotherapy (THE/TTE)
![Page 17: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/17.jpg)
CROSS Trial: Resection rate and resection
margins
Resection rate of all randomized patients
Surgery alone CRT + surgery
186/188 (99%) 168/178 (95%)
Resection margins
Surgery alone CRT + surgery
R0 111/161 (69%) 148/161 (92%) p<0.002
ITT R0 111/188 (59%) 148/178 (83%)
R0 = no tumor within 1 mm of the resection margins
CROSS study16
![Page 18: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/18.jpg)
OS and Outcomes Improved with Chemo RT + Surgery
•5-year survival 47% versus
34%
•Squamous HR 0.48 (p = 0.008)
• OS 81.6 mo vs 21.1 mo
• PFS 74.7 mo vs 11.6 mo
•Local progression all patients
22% CRT + S vs 38% S
•pCR : 49% SCC
•Low operative mortality: 2-3%
Shapiro J, Lancet Oncol 16: 1090; 2015
![Page 19: Management of Squamous Cell Cancer of · Outcome of non randomized, non responder patients: Bedenne Trial 112 of 192 non randomized / nonresponder pts (58%) went to surgery, R0 71%](https://reader035.fdocuments.in/reader035/viewer/2022081409/6089cc17e69f8a681171e55c/html5/thumbnails/19.jpg)
Esophageal Squamous Cancer: Chemo RT + Surgery is Favored
Highest overall survival achieved with CRT + S
– Significant reductions in local recurrence
All patients should be considered for surgery
Surgery in non responders achieves long term survival
Patients with good response to CRT
– Individualize the role of surgery vs observation
– Medically fit patients for surgery
Better means to ID residual disease